Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Gynae 2021 | Overcoming resistance to PARPi in ovarian cancer

Domenica Lorusso • 7 Jul 2021
ESMO Gynae 2021
Gynecological Cancer Ovarian Cancer

Overcoming resistance to PARP inhibitions is an area of unmet need in ovarian cancer. Domenica Lorusso, MD, PhD, Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy, speaks on the importance of elucidating the mechanisms of PARP inhibiton resistance in ovarian cancer, and its importance in terms of improving patient stratification for therapeutic strategies. This interview took place at the ESMO Gynaecological Cancers Virtual Congress 2021.

More from Domenica Lorusso

0:47
Assessing chemotherapy and immunotherapy in dMMR endometrial cancer
Domenica Lorusso • 23 Oct 2023
0:39
ESMO 2023 highlights: KEYNOTE-A18 and more
Domenica Lorusso • 23 Oct 2023
0:52
The importance of HRD testing in ovarian cancer
Domenica Lorusso • 23 Oct 2023
1:14
KEYNOTE-A18: pembrolizumab with chemoradiotherapy for advanced cervical cancer
Domenica Lorusso • 23 Oct 2023

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals